Secondary dentine

disease
On this page

Also known as DENTIN SECONDDentin, SecondaryDentins, SecondaryIrregular dentinIrregular dentineReparative dentineSclerotic dentineSECOND DENTINSecondary DentinSecondary DentinsTertiary dentine

Summary

Secondary dentine (MONDO:0020818) is a disease and 2 clinical trials. Top therapeutic interventions include potassium iodide, silver diammine fluoride, and potassium ion. A subtype of dental pulp disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namesecondary dentine
Mondo IDMONDO:0020818
MeSHD003809
SNOMED CT59818004
UMLSC0011434
MedGen3746
Is cancer (heuristic)no

Also known as: DENTIN SECOND · Dentin, Secondary · Dentins, Secondary · Irregular dentin · Irregular dentine · Reparative dentine · Sclerotic dentine · SECOND DENTIN · Secondary Dentin · Secondary dentin · secondary dentin · secondary dentine · Secondary Dentins · Tertiary dentine

Disease family

This is a subtype of dental pulp disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorderskeletal system disordertooth disorderdental pulp disordersecondary dentine

Related subtypes (6): pulp degeneration, dental pulp necrosis, pulp erosion, dental pulp calcification, pulpitis, exposure, dental pulp

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE2/PHASE31
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04236830PHASE2/PHASE3COMPLETEDSilver Diamine Fluoride/ Potassium Iodide in Indirect Pulp Capping of Young Permanent Molars
NCT05211908Not specifiedUNKNOWNClinical Performance of Different Adhesive Strategies With a Universal System in Sclerosed Dentin in NCCL: A Double-blind Randomized Clinical Trial.

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
POTASSIUM IODIDE41
SILVER DIAMMINE FLUORIDE31
POTASSIUM ION01